Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics
Study Details
Study Description
Brief Summary
This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401(insulin degludec/insulin aspart (IDegAsp)) with NN1250 (insulin degludec (IDeg)) and insulin aspart (IAsp) in subjects with type 1 diabetes where the trial participant will receive one single dose of each trial product in varying order.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: IDeg
|
Drug: insulin degludec
Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
|
Experimental: IDegAsp
|
Drug: insulin degludec/insulin aspart
Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
|
Active Comparator: IAsp
|
Drug: insulin aspart
Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
|
Outcome Measures
Primary Outcome Measures
- Area under the glucose infusion rate curve [From 0 to 6 hours after single-dose administration]
- Area under the glucose infusion rate curve [From 4 to 24 hours after single-dose administration]
Secondary Outcome Measures
- Area under the insulin degludec concentration-time curve [From 0 to 120 hours after single-dose administration]
- Maximum observed insulin degludec concentration [From 0 to 120 hours after single-dose administration]
- Area under the insulin aspart concentration-time curve [From 0 to 12 hours after single-dose administration]
- Maximum observed insulin aspart concentration [0-12 hours after single-dose administration]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
-
Body mass index 18.0-28.0 kg/m^2 (both inclusive)
Exclusion Criteria:
-
Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
-
Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day).
-
Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Neuss | Germany | 41460 |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Global Clinical Registry (GCR, 1452), Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- NN5401-1977
- 2008-008357-32
- U1111-1111-9043